CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 277 filers reported holding CLOVIS ONCOLOGY INC in Q2 2017. The put-call ratio across all filers is 0.51 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $45,000 | -15.1% | 1,000 | 0.0% | 0.02% | -5.9% |
| Q1 2018 | $53,000 | -23.2% | 1,000 | -1.5% | 0.02% | -22.7% |
| Q4 2017 | $69,000 | -24.2% | 1,015 | -7.7% | 0.02% | -26.7% |
| Q3 2017 | $91,000 | -12.5% | 1,100 | -1.3% | 0.03% | -23.1% |
| Q2 2017 | $104,000 | -26.2% | 1,115 | -49.7% | 0.04% | -29.1% |
| Q1 2017 | $141,000 | +43.9% | 2,215 | 0.0% | 0.06% | +34.1% |
| Q4 2016 | $98,000 | -44.0% | 2,215 | -54.5% | 0.04% | -46.8% |
| Q3 2016 | $175,000 | +161.2% | 4,865 | 0.0% | 0.08% | +148.4% |
| Q2 2016 | $67,000 | +31.4% | 4,865 | +81.8% | 0.03% | +10.7% |
| Q1 2016 | $51,000 | -42.7% | 2,676 | +5.5% | 0.03% | -45.1% |
| Q4 2015 | $89,000 | -21.9% | 2,536 | +104.0% | 0.05% | -29.2% |
| Q3 2015 | $114,000 | +12.9% | 1,243 | +8.1% | 0.07% | +16.1% |
| Q2 2015 | $101,000 | – | 1,150 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
| EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
| Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
| NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
| Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
| Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
| CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
| PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
| HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |